The cytotoxic T Lymphocyte (CTL) response is recognized as perhaps the most relevant functional measure that reflects cell-mediated acquired immune defense against viral infections and cancer. The CTL responses can evaluate effective antigen presentation by tumors and is a key assessment in how well a drug candidate enhances CTL responses in eradicating or killing tumors. IMMUNE 3D® is a physiologically relevant platform that is designed to capture the immune-tumor interactions in the presence of tumor environment cells. This assay utilizes our proprietary HLA-matched CTL and tumor cell lines and is run in a 24 well format.
The assay is run in a 24 well plate and can accommodate up to 7 doses of the drug candidate. Each dose is a well. Each dose is run in duplicates (2 times)
We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.